Skip to main content
SpringerLink
Log in

Evidence that 5-HT2 antagonism elicits a 5-HT3-mediated increase in dopamine transmission

  • Original Paper
  • Published:
Journal of Biomedical Science

Abstract

Amperozide, a novel atypical antipsychotic drug with few extrapyramidal side effects, is a strong serotonin2 (5-HT2) antagonist but has low affinity for dopamine receptors in vitro. The effect of amperozide on the dopaminergic synapse was studied with an in vivo microdialysis technique using anesthetized male Sprague-Dawley rats. Following implantation of dialysis probes into the striatum and nucleus accumbens (NuAc), amperozide was intravenously infused as six consecutive incremental doses (0.5, 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg) at intervals of 15 min. From the beginning of drug infusion, perfusates were collected in fractions every 30 min throughout a total period of 120 min. The samples were then immediately analyzed by high-performance liquid chromatography with electrochemical detection. Amperozide induced a dose-related elevation of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindolacetic acid (5-HIAA) levels in both areas.p-Chlorophenylalanine (pCPA) pretreatment abolished the production of 5-HIAA in both areas and attenuated the amperozide-induced rise of DOPAC but not of dopamine. After pretreatment with an intravenous 5-HT3 antagonist, MDL 72222, the amperozide-induced changes in dopamine, DOPAC and 5-HIAA in both areas were lower than in the saline control group. Preliminary data showed that afterpCPA pretreatment, incremental concentrations of the 5-HT3 agonist 1-(m-chlorophenyl)-biguanide perfused via the probe also produced significant elevation of dopamine and DOPAC levels in these two areas. Taken together, these results suggest that amperozide may directly block 5-HT2 receptors in the striatum and NuAc, thereby enhancing 5-HT transmission. The enhanced 5-HT transmission may activate postsynpatic 5-HT3 receptors located on the dopaminergic terminals, leading to changes in dopamine transmission in these two areas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ashby CR, Wang RY. Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: Microiontophoretic studies. Brain Res 506:346–348;1990.

    Google Scholar 

  2. Axelsson R, Nisson A, Christensson E, Björk A. Effects of amperozide in schizophrenia. Psychopharmacology 104:287–292;1991.

    Google Scholar 

  3. Blandina P, Goldfarb J, Green JP. Activation of 5-HT3 receptor releases dopamine from rat striatal slice. Eur J Pharmacol 155:349–350;1988.

    Google Scholar 

  4. Carboni E, Acquas E, Leone P, Perezzani L, Di Chiara G. 5-HT3 receptor antagonists block morphine- and nicotine-induced place-preference conditioning. Eur J Pharmacol 151:159–160;1988.

    Google Scholar 

  5. Chen J, Van Praag HM, Gardner EL. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 543:354–357;1991.

    Google Scholar 

  6. Chesselet MF. Presynaptic regulation of neurotransmitter release in the brain. Neuroscience 12:347–375;1984.

    Google Scholar 

  7. Christensson E, Björk A. Amperozide: A new pharmacological approach in the treatment of schizophrenia. Pharmacol Toxicol 66:5–7;1990.

    Google Scholar 

  8. Costall B, Domeney AM, Naylor RJ, Tyers MB. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894;1987.

    Google Scholar 

  9. De Simoni MG, Toso GD, Sokola FA, Algeri S. Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferents. Brain Res 411:81–88;1987.

    Google Scholar 

  10. Drag A, Gonye TJ, Oakley NR, Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 113:45–57;1976.

    Google Scholar 

  11. Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 155:33–36;1989.

    Google Scholar 

  12. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24;1991.

    Google Scholar 

  13. Graybiel AM, Ragsdale CW Jr. Biochemical anatomy of the striatum. In: Emson PC, ed. Chemical Neuroanatomy. New York, Raven, 427–504;1983.

    Google Scholar 

  14. Gustafsson B, Christensson E. Amperozide and emotional behaviour. Pharmacol Toxicol 66:34–39;1990.

    Google Scholar 

  15. Higgins GA, Jones BJ, Oakley NR, Michael BT. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology 104:545–551;1991.

    Google Scholar 

  16. Ichikawa J, Meltzer HY. Amperozide, a novel antipsychotic drug, inhibits the ability ofd-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58:2285–2291;1992.

    Google Scholar 

  17. Jacobs BL, Azmitia E. Structure and function of the brain serotonin system. Physiol Rev 72:65–230;1992.

    Google Scholar 

  18. Jiang LH, Ashby CR, Kasser RJ, Wang RY. The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: An in vivo chronocoulometric study. Brain Res 513:156–160;1990.

    Google Scholar 

  19. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253:803–811;1990.

    Google Scholar 

  20. Koulu M, Sjöholm B, Lappalainen J, Virtanen R. Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur J Pharmacol 169:321–324;1989.

    Google Scholar 

  21. Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9:2051–2065;1989.

    Google Scholar 

  22. Lewis DA, Hayes TL, Lund JS. Dopamine and the neural circuitry of primate prefrontal cortex: Implications for schizophrenia research. Neuropsychopharmacology 6:127–134;1992.

    Google Scholar 

  23. McGeer PL, Eccles SJC, Mcgeer EG. Serotonin and other brain indoles. In: Molecular Neurobiology of the Mammalian Brain, ed 2. New York, Plenum, 319–348;1987.

    Google Scholar 

  24. McGeer PL, Eccles SJC, Mcgeer EG. Catecholamine neurons. In: Molecular Neurobiology of the Mammalian Brain, ed 2. New York, Plenum, 265–318;1987.

    Google Scholar 

  25. Moghaddam B, Bunney BS. Acute defects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rats: An in vivo microdialysis study. J Neurochem 54:1755–1760;1990.

    Google Scholar 

  26. Nissbrandt H, Sundstrom E, Jonsson G, Hjorth S, Carlsson A. Synthesis and release of dopamine in rat brain: Comparison between substantia nigra pars compacta, pars reticulate, and striatum. J Neurochem 52:1170–1182;1989.

    Google Scholar 

  27. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147–156;1994.

    Google Scholar 

  28. Reinhard JF Jr, Wurtman RJ. Relation between brain 5-HIAA levels and the release of serotonin into brain synapses. Life Sci 21:1741–1746;1977.

    Google Scholar 

  29. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 13:116–121;1992.

    Google Scholar 

  30. Soghomonian JJ, Doucet G, Descarries L. Serotonin innervation in adult rat neostriatum. I: Quantifies regional distribution. Brain Res 425:85–100;1987.

    Google Scholar 

  31. Sorensen SM, Humphreys TM, Palfreyman MG. Effect of acute and chronic MDL 73, 147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115–118;1989.

    Google Scholar 

  32. Svartengren J, Simonsson P. Receptor binding properties of amperozide. Pharmacol Toxicol 66:8–11;1990.

    Google Scholar 

  33. Ugedo L, Grenhoff J, Svensson TH. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45–50;1989.

    Google Scholar 

  34. Waeber C, Dixon K, Hoyer D, Palacios JM. Localization by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. Eur J Pharmacol 151:351–352;1988.

    Google Scholar 

  35. Westerink BHC, Tuntler J, Damsma G, Rollema H, de Vries JB. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Nauyn Schmiedebergs Arch Pharmacol 336:502–507;1987.

    Google Scholar 

  36. Wightman RM, Zimmerman JB. Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res 15:135–144;1990.

    Google Scholar 

  37. Yamamoto BK, Meltaer HY. The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. J Pharmacol Exp Ther 263:180–185;1992.

    Google Scholar 

  38. Zetterstrom T, Sharp T, Collin AK, Ungerstedt U. In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs: Implications for the origin of extracellular DOPAC. Eur J Pharmacol 148:327–334;1988.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Biophysics, National Defense Medical Center, PO Box 90048-503, Taipei, Taiwan, ROC

    Wan-Hsun Wu, Nai-Kuei Huang, Tsai-Hsin Yin & Che-Se Tung

  2. Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China

    Nai-Kuei Huang & Che-Se Tung

  3. Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan, Republic of China

    Ching-Jiunn Tseng

Authors
  1. Wan-Hsun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nai-Kuei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ching-Jiunn Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsai-Hsin Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Che-Se Tung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, WH., Huang, NK., Tseng, CJ. et al. Evidence that 5-HT2 antagonism elicits a 5-HT3-mediated increase in dopamine transmission. J Biomed Sci 2, 174–182 (1995). https://doi.org/10.1007/BF02253069

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02253069

Key Words

Search

Navigation